Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2019

View Archived Issues

Biogen initiates phase I study of BIIB-094 in patients with Parkinson's disease

SVI and Janssen extend collaboration agreement with focus on Alzheimer's disease treatment

Autogramins inhibit the cholesterol-transfer protein GRAMD1A, involved in autophagy regulation

RIPK1 regulates necrosis of acinar cells in early acute pancreatitis

New mouse models for human lung infections

Synthetic oligosaccharide-protein conjugate N. meningitidis vaccine is immunogenic in vivo

Krystal Biotech initiates phase I/II study of topical KB-105 gene therapy for TGM1-deficient ARCI

New phase I trial to study gene therapy for APOE4 homozygotes with Alzheimer's disease

Medshine Discovery divulges new KDM5A inhibitors

MiR-125a-5p identified as tumor suppressor and biomarker in head and neck cancer

Ancureall Biomedical Technology identifies CDK9 inhibitors

Sunshine Lake Pharma discloses BIRC3 inhibitors

Novel organoid models cover a wide range of endometrial diseases

Genifarm Laboratories and SCUT patent new compounds for cancer

Chinese investigators present adenosine A2A receptor antagonists

New human antibody targeting PSMA inhibits prostate cancer tumor growth

One and done: Engineered oncolytic virus can invite T cells, feed them lunch

A reverse engineering approach for in vitro modeling of the human eye

TLR4 agonist INI-2004 as immunostimulant for the treatment of infectious diseases

Phase II data reported for P2Y12 inhibitor selatogrel in CAD patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.